ISRCTN35210312已完成未知
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes
Okhotsk-kai Hospital (Japan)0 个研究点目标入组 36 人开始时间: 2007年8月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
2008 Results article in https://pubmed.ncbi.nlm.nih.gov/19149832/ (added 29/10/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with type 2 diabetes under long-term insulin injection
- •2. Age between 40 and 86 years
- •3. Insulin dosage >10 units/24 h
- •4. Insulin injection duration >3 months
- •5. C-peptide in 24-hr urine >10 micrograms
- •6. Fasting CPR >0.5 ng/ml
排除标准
- •1. Positive for glutamine acid decarboxylase antibody
- •2. ALT and/or AST >3 times the upper limit of normal
- •3. Presently and/or in the past suffering from heart failure
- •4. Ejection fraction assessed by echocardiography <40%
- •5. Malignancy on active therapeutic regimen or without complete remission or cure
- •6. Concomitantly suffering from infection
- •7. Planning to have surgery
- •8. >50% positivity for insulin antibody
- •9. Diagnosis of type I diabetes
- •10. Pregnant or breast feeding
- •11. Under dialysis
- •12. Concomitantly using pioglitazone
研究者
相似试验
已完成
不适用
Switch to oral hypoglycemic agent therapy from insulin injectioJPRN-UMIN000007051Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science,60
已完成
不适用
Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2)Type2 DiabetesJPRN-UMIN000008944Department of Medicine, Shiga University of Medical Science15
已完成
不适用
Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injectioType2 DiabetesJPRN-UMIN000007894Department of Medicine, Shiga University of Medical Science15
已完成
不适用
Therapeutic implications of oral hypoglycaemic agents on the enteroinsular axis in type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitusISRCTN37245053Royal Victoria Hospital (UK)40
已完成
不适用
Glycaemic control and prevention of hypoglycaemia in intensively treated subjects with type 1 diabetes using Accu-Chek® advisor insulin guidance softwareNutritional, Metabolic, EndocrineType 1 DiabetesDiabetesISRCTN66986330Roche Diagnostics Corporation (USA)123